Precision Medicine Diagnostics
News and analysis on diagnostic technologies and applications for precision medicine.
Dyne Reports on Response Predictive Biomarkers for Neurodegenerative Disorder Genetic Medicine
Premium
The ASO for myotonic dystrophy type 1 was well tolerated and improved splicing and function in a study presented at ASGCT.
Data from the EMBARK trial suggest patients may have functional improvements taking the gene therapy between 8 and 9 years old.
Real-World Data Show 72 Percent of Bladder Cancer Patients Got Genomic Testing in Community Network
Premium
The analysis by Ontada tracked testing rates within the US Oncology Network for PD-L1, FGFR2/3, and HER2 biomarkers over 10 years.
The firms launched the global Phase II bladder cancer trial for autogene cevumeran after seeing early success in pancreatic cancer.
In a Phase Ia trial in ovarian cancer, a strong neutralizing antibody response correlated with better disease control and longer survival.
May 16, 2025
May 16, 2025
May 14, 2025